Holmström, M O
Martinenaite, E
Ahmad, S M
Met, Ö
Friese, C
Kjær, L
Riley, C H
thor Straten, P http://orcid.org/0000-0002-4731-4969
Svane, I M
Hasselbalch, H C
Andersen, M H
Article History
Received: 22 March 2017
Revised: 15 June 2017
Accepted: 23 June 2017
First Online: 5 July 2017
Competing interests
: The authors declare no conflict of interest. However, it should be noted that Morten Orebo Holmström, Hans Carl Hasselbalch and Mads Hald Andersen have filed a patent regarding theCALRexon 9 mutations as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region, and Copenhagen University Hospital at Herlev, Capital Region, according to Danish Law concerning inventions made at public research institutions.